Cost-effectiveness of pharmacogenetic testing to tailor smoking-cessation treatment

• Published in: The pharmacogenomics journal Vol. 8; no. 6; pp. 391 - 399
• Main Authors: Heitjan, D F, Asch, D A, Ray, Riju, Rukstalis, Margaret, Patterson, Freda, Lerman, C
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 01.12.2008; Nature Publishing Group
• Subjects: Benzazepines - administration & dosage; Benzazepines - pharmacology; Biomedical and Life Sciences; Biomedicine; Bupropion; Bupropion - administration & dosage; Bupropion - pharmacology; Care and treatment; Cigarette smoking; Cost analysis; Cost-Benefit Analysis; Drug addiction; Economic aspects; Gene Expression; Genetic aspects; Genetic screening; Genotype; Human Genetics; Humans; Monte Carlo simulation; Nicotine; Oncology; original-article; Pharmacogenetics; Pharmacotherapy; Psychopharmacology; Quinoxalines - administration & dosage; Quinoxalines - pharmacology; Receptors, Nicotinic - drug effects; Sensitivity analysis; Smokers; Smoking; Smoking Cessation - economics; Smoking cessation products; Varenicline; United States; tobacco dependence; genetic testing; Monte Carlo simulation; addiction

We evaluated the cost-effectiveness of a range of smoking cessation drug treatments, including varenicline, transdermal nicotine (TN), bupropion and the use of a genetic test to choose between TN and bupropion. We performed Monte Carlo simulation with sensitivity analysis, informing analyses with pu...